3 Aug
2021

Pfizer gets boost in landmark $1 billion pregabalin patent damages dispute

The UK Patents Court has sided with Pfizer on key counterfactual assumptions in its first-of-a-kind compensation battle following the revocation of a second medical use patent for pregabalin.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth